EpiVax Upgrades Immunogenicity Platform with AI-Driven Tools

The rollout centers on JanusMatrix 2.1, which utilizes artificial intelligence to weight epitope cross-conservation against specific prevalence and expression data. This allows for a more nuanced understanding of immune tolerance. By incorporating these findings into the new JanusMatrix-Adjusted EpiMatrix score, researchers gain a clearer picture of intrinsic effector epitope density across various therapeutic modalities.

EpiVax also launched ADA 2.2, an updated anti-drug antibody prediction model. By merging epitope-based analysis with biophysical attributes and specific mode-of-action criteria, the tool shows a stronger correlation with clinical observations than previous iterations. These additions arrive as regulators like the FDA push for the adoption of human-relevant New Approach Methodologies, offering developers a pathway to identify immune liabilities earlier in the drug discovery process.